Table 1.
Demographics and Baseline Characteristics for Oritavancin-Treated Patients
| Characteristic | Value or No. (%) |
|---|---|
| Age, y | |
| Mean (SD) | 57.8 (16.4) |
| Median (IQR) | 58.7 (46.8–69.6) |
| Range | 18–98 |
| ≥65 y | 37.0 |
| Male, % | 53.2 |
| Race, white, % | 93.0 |
| BMI, kg/m2 | |
| Mean (SD) | 32.8 (9.0) |
| Median (IQR) | 31.4 (26.2–38.0) |
| Range | 14–65 |
| SIRS at presentation, No. (%)a | 37 (8.3) |
| Temperature >38ºC, No. (%) | 9 (2.0) |
| WBC > 12 000 cells/mm3, No. (%) | 38 (15.6) |
| Comorbidities, No. (%) | |
| Hypertension | 235 (53.4) |
| Diabetes mellitus | 174 (39.5) |
| Diabetic neuropathy | 54/174 (31.0) |
| Diabetic foot infection | 38/174 (21.8) |
| Hyperlipidemia | 138 (31.4) |
| Peripheral vascular disease/lymphedema | 76 (17.3) |
| Coronary artery disease | 63 (14.3) |
| COPD/asthma | 58 (13.2) |
| Chronic kidney disease | 41 (9.3) |
| Neoplastic disease | 31 (7.0) |
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; IQR, interquartile range; SIRS, systemic inflammatory response syndrome; WBC, white blood cell count.
aSystemic inflammatory response syndrome is defined as 2 of the following: temperature >38°C, pulse >90 beats per minute, respiratory rate >20 breaths per minute, white blood cell count >12 000 mm3 or <4000 mm3, or >10% bandemia.